$130,358.93 ownership Payment -- Allergan (AbbVie) to Dr. Karen Harris

Dermatologist Receives Over $130K Ownership Interest from Allergan (AbbVie)

This page provides a detailed analysis of a $130,358.93 ownership payment from Allergan (AbbVie) to Dr. Karen Harris. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$130,358.93
Payment Typeownership
Payment NatureOwnership or Investment Interest
Pharmaceutical CompanyAllergan (AbbVie)
PhysicianDr. Karen Harris
NPI Number1806248054
Physician SpecialtyDermatology
LocationCity, MN
Date of Payment2025-06-18
Conflict AssessmentHigh -- Significant

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Allergan (AbbVie) made a $130.4K ownership payment to Karen Harris, a Dermatology specialist in City, MN. This record details a significant ownership interest payment of $130,358.93 to Dr. Karen Harris, a dermatologist in MN. The payment from Allergan (AbbVie) was made on June 18, 2025, and is categorized as an 'Ownership or Investment Interest'. This type of payment can indicate a financial relationship beyond standard consulting or speaking fees.

Patient Guidance: What This Payment Means for You

If your doctor has an ownership interest in a company, it means they may financially benefit from the products that company makes or sells. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Ownership interests can represent significant financial relationships, and their prevalence varies by specialty; dermatologists may have more such arrangements compared to other fields.

Regulatory Context: Sunshine Act Requirements

Payments for ownership or investment interests are reportable under the Sunshine Act, requiring disclosure of financial relationships between drug manufacturers and healthcare providers.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding ownership Payments

Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.

Frequently Asked Questions About This Payment

What was this $130.4K payment for?

This was a ownership payment of $130.4K from Allergan (AbbVie) to Karen Harris, categorized as "Ownership or Investment Interest". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Karen Harris accept pharmaceutical money?

Yes, Karen Harris received this $130.4K payment from Allergan (AbbVie). Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Karen Harris's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this ownership payment?

A ownership payment of $130.4K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Dermatology?

To compare this payment against Dermatology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Dermatology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Karen Harris's relationship with Allergan (AbbVie)?

The substantial amount suggests a potentially deep financial tie between the physician and the pharmaceutical company. This $130.4K ownership payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Dermatology?

The payment date is in the future (2025), which is unusual for reported historical data.

What should patients do after learning about this payment?

If your doctor has an ownership interest in a company, it means they may financially benefit from the products that company makes or sells.

What else should I know about this ownership payment?

Dermatology is a specialty where such ownership interests might be more common due to product development or investment opportunities.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.